An Exploratory Clinical Study of Short-course Radiotherapy Combined With Envafolimab, Endostatin and SOX Regimen for Neoadjuvant Treatment of Resectable Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 29 Feb 2024
At a glance
- Drugs Endostatin (Primary) ; Envafolimab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms NEO-EGA
Most Recent Events
- 31 Jan 2024 Recruitment completion is expected on 30 Jan 2025, according to ISRCTN: Current Controlled Trials.
- 26 May 2022 New trial record